1. Home
  2. TARS vs BATRK Comparison

TARS vs BATRK Comparison

Compare TARS & BATRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TARS
  • BATRK
  • Stock Information
  • Founded
  • TARS 2016
  • BATRK 1991
  • Country
  • TARS United States
  • BATRK United States
  • Employees
  • TARS N/A
  • BATRK N/A
  • Industry
  • TARS Medicinal Chemicals and Botanical Products
  • BATRK Broadcasting
  • Sector
  • TARS Health Care
  • BATRK Industrials
  • Exchange
  • TARS Nasdaq
  • BATRK Nasdaq
  • Market Cap
  • TARS 2.8B
  • BATRK 2.5B
  • IPO Year
  • TARS 2020
  • BATRK N/A
  • Fundamental
  • Price
  • TARS $77.39
  • BATRK $38.39
  • Analyst Decision
  • TARS Strong Buy
  • BATRK Strong Buy
  • Analyst Count
  • TARS 7
  • BATRK 3
  • Target Price
  • TARS $69.86
  • BATRK $58.00
  • AVG Volume (30 Days)
  • TARS 461.9K
  • BATRK 329.1K
  • Earning Date
  • TARS 11-04-2025
  • BATRK 11-05-2025
  • Dividend Yield
  • TARS N/A
  • BATRK N/A
  • EPS Growth
  • TARS N/A
  • BATRK N/A
  • EPS
  • TARS N/A
  • BATRK N/A
  • Revenue
  • TARS $366,100,000.00
  • BATRK $723,307,000.00
  • Revenue This Year
  • TARS $139.46
  • BATRK N/A
  • Revenue Next Year
  • TARS $49.91
  • BATRK N/A
  • P/E Ratio
  • TARS N/A
  • BATRK N/A
  • Revenue Growth
  • TARS 182.44
  • BATRK 6.62
  • 52 Week Low
  • TARS $38.51
  • BATRK $35.46
  • 52 Week High
  • TARS $78.76
  • BATRK $47.18
  • Technical
  • Relative Strength Index (RSI)
  • TARS 66.65
  • BATRK 36.17
  • Support Level
  • TARS $70.84
  • BATRK $38.29
  • Resistance Level
  • TARS $78.76
  • BATRK $39.64
  • Average True Range (ATR)
  • TARS 3.29
  • BATRK 0.91
  • MACD
  • TARS 0.35
  • BATRK -0.10
  • Stochastic Oscillator
  • TARS 88.54
  • BATRK 10.98

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

About BATRK Atlanta Braves Holdings Inc. Series C

Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.

Share on Social Networks: